Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do they have the facilities to produce enough drugs to capture even ten percent of the opiate market along with the other 20 plus drugs that are either in the pipeline or are already being shipped?
I would guess no, (I have no knowledge of what it would take for space and staffing)
I know this ramp up will take several years and they may lease more space and attempt to tackle it themselves.
My guess is they sell the company to the highest bidder sometime in the next year.
OT Conix ,I don't think the other company that we both know about will ever end up impacting the pain management field. I don't own any presently but might buy back if they change management.
GLTA
Agree 100 %
poorme
We have not even had a pr on the patent.
After that, all the analysis and attention will come.
We ran from .082 to .125 in two trading days a little breather is not a bad or unexpected thing.
I think we will see news in a day or two, it may take a month and thats ok by me as I know and understand the potential risk is small and the potential reward is great.
Relax and let it play out.
Its amazing to me that people will jump out tomorrow because the volume has slowed and the news is not out yet.
I once had a company that did a rs. They did it to move to another exchange. The price doubled in about 2 weeks.
GLTA
Up 2 cents on relatively light volume.
Not a lot of sellers.
I would rather have a steady climb but I think we will have some wild and crazy trading day ahead.
GLTA
I would not be surprised to see some large volume days with spikes based solely on charts.
The news will be digested slowly by the market. imho
But it won't take a lot of recognition to have a large amount of appreciation.
As shareholders begin to understand the gravity of the patent it will become very difficult for others to accumulate a position of any size.
imho
Purdue, OxyContin Maker, Races Rivals to Deter Abuse
By Catherine Larkin April 28 (Bloomberg)
Purdue Pharma LP, the maker of the painkiller OxyContin, is racing smaller drug companies to introduce tamper-resistant pills that addicts can't abuse.
Closely held Purdue agreed last year to pay $634.5 million to settle claims that promotions from 1996 to 2001 misled doctors about the risks of OxyContin, its best- selling product with more than $1 billion in sales last year. A generic version was among the medicines taken by actor Heath Ledger in his fatal overdose in February.
The Stamford, Connecticut-based drugmaker will ask a joint panel of U.S. advisers next
week to back a new OxyContin formula that may prevent abusers from crushing the pill
or dissolving it in alcohol to release several hours of narcotics at once. Pain Therapeutics Inc., Alpharma Inc. and Elite Pharmaceuticals Inc. predict a $1 billion market for alternatives they're developing even if Purdue beats them to pharmacies.
``This is clearly a defensive move by Purdue recognizing that their OxyContin franchise is in danger,'' said E. Russell McAllister, an analyst who covers Pain Therapeutics at Merriman Curhan Ford & Co. in Portland, Oregon, in a phone interview. ``All the drugs coming down the pipeline are better than what's on the market, and presumably the new OxyContin formula.''
Pain Therapeutics was unchanged at $6.95 in Nasdaq Stock Market composite trading at 4 p.m. New York time and has lost 12 percent in the past 12 months. Alpharma rose 19 cents to $25.79 on the New York Stock Exchange, capping a 5.2 percent increase in the past 12 months. Elite gained 11 cents, or 17 percent, to 76 cents on the American Stock Exchange and has fallen 68 percent in the past 12 months.
$6.37 Billion Sales
U.S. sales of prescription opioids -- drugs including OxyContin derived from the opium poppy -- surged to $6.37 billion last year, a 52 percent gain from 2002, according to IMS Health Inc., a Norwalk, Connecticut research firm. Also in the group are fentanyl drugs including Cephalon Inc.'s Fentora and Actiq, hydrocodone drugs including Abbott Laboratories' Vicodin, morphine and codeine.
Doctors considered sustained release, high-dose painkillers a major breakthrough for
cancer and chronic pain when introduced in the mid-1990s, though the drugs were easy to manipulate. As many as 4 percent of high school students and 3 percent of young
adults say they've used OxyContin in the past year, according to a Monitoring the Future study released last year by the National Institute on Drug Abuse.
About 10 billion doses of these drugs are now dispensed yearly in the U.S., and use may rise after the new formulas are introduced, said Nathaniel Katz, head of the
Program on Opioid Risk Management at Tufts University in Boston and a consultant to companies developing abuse-resistant painkillers.
`Untapped Market'
``Eventually these drugs will replace the existing drugs and there will be liabilities for doctors who don't make the switch,'' Katz said in a phone interview. ``There's plenty of room in this essentially untapped market.''
Outside advisers to the Food and Drug Administration will consider Purdue's new formula May 5 in Gaithersburg, Maryland. Pain Therapeutics, Alpharma and Elite fell as
much as 10 percent in New York trading after the meeting was announced and say they plan to attend to get a better sense of the competition.
Purdue hasn't disclosed how its new OxyContin technology works or how effective it has
been in studies. A review of pending patents suggests the pill has ``rubbery characteristics'' to prevent tampering and may release no more than a quarter of its active ingredient when dissolved in ethanol, said Corey Davis, a Natixis Bleichroeder analyst, in a March 31 note to clients.
The new OxyContin formula may be approved by July, at least six months ahead of any competitors, Davis said.
Targets for Abuse
While opioids are an important tool in managing pain, they are ``targets for illegal trafficking and abuse,'' said Purdue spokesman James Heins in an e-mailed message.
``As long as they are equally safe and effective for patients, having new tamper-
resistant formulations in the marketplace could have a significant public health benefit,'' Heins said.
A taffy-like version of oxycodone, the active ingredient in OxyContin, is being developed by Pain Therapeutics, of San Mateo, California, and partner King Pharmaceuticals Inc.,
of Bristol, Tennessee. The gummy texture of the capsule, Remoxy, is difficult for abusers to convert into a form that can be injected or snorted and resists dissolving in alcohol and water.
The companies plan to submit Remoxy this quarter for FDA approval.
``Up until about a year ago, a bunch of investors were really still pooh-poohing it,'' said Remi Barbier, chief executive officer of Pain Therapeutics, in a phone interview. ``People have shifted from `Who needs it?' to `Who's going to win the billion-dollar market?'''
Using a Chemical
Alpharma and Elite are counting on the chemical naltrexone, which can counteract most
of the euphoria gained from opioids. Their painkillers include naltrexone encased in a protective coating that allows the chemical to pass through the digestive tract unabsorbed when the drug is taken as directed.
When the pill is crushed, chewed or cut open, the naltrexone is released along with the narcotic, preventing it from causing a high.
Embeda, an extended-release morphine pill being developed by Alpharma, has a kernel
of natrexone at its center. The Bridgewater, New Jersey-based drugmaker submitted Embeda to the FDA in February and then retracted its request for approval April 21 to
revise undisclosed technical issues. Alpharma said it plans to resubmit the application as soon as possible.
ELI-216, a once-a-day capsule made by Elite of Northvale, New Jersey, contains tiny
pellets of naltrexone and oxycodone. Elite said it plans to start the final stage of testing ELI-216 in people soon.
King is also testing a painkiller called Acurox that combines oxycodone with the chemical niacin, which causes facial flushing if taken in excess.
Next week,
It is impossible for anyone to know where it will go.
One thing is for sure is that eltp is more valuable with the patent than without.
imo
Minimally I would suspect we get a new much higher base.
If the Euro partner is identified along with the patent news, or any of the other potential news comes out a few days before or after the patent news, then all bets are off.
Things age really coming together for eltp on a lot of fronts.
They will not be under the radar for much longer if at all.
All imo
GLTA
I really appreciate all who have done and posted some very in-depth DD.
Glad I have been accumulating pretty heavy for the last 5 months.
Thanks again
GLTA
Hey Dr l
If Purdue has the patents for a process/product that will do what elite claims their product will do, what has been the holdup in bringing it to market?
Purdue's products are not on the market yet why?
Seems like they would be fast tracked with the demand for such a tech?
GLTA
My guess is we get a little run in the last few minutes.
But it really matters very little.
We could close at .08 and i would be happy.
This is big news and will be disseminating for weeks if not months.
GLTA
Ya it sure does.
I called a person this am and they got in in the high .08s.
Looks like a no brainer.
Not a lot of sellers.
Not seeing those huge numbers on the ask.
Big Congrats to all who have held.
I have been in for a little over a year.
GLTA
Dr L I think we might see just a tad more than 30% once this gets a pr. lol
Also if its the same tech eltp would not get a patent for it, unless maybe Dr L knows more than the patent office.
Dr L
Very insightful.
Wow, never really believed this would happen.
I had hope .
All opiates, wow.
Looks like it is just a matter of a short period of time.
I don't know what snags can happen at this point, but nothing like what they have already overcome.
"She stated that this would be ground breaking".
Picked up another 10k at .082.
Could not resist, although since there is no pr until the patent is checked and paid for, there may be more opportunities to pick it up down here.
There are many folks like conix waiting for the chart to turn and are not really watching the fundamentals as closely as the charts.
GLTA
Thanks good info.
I wonder if they will pr it before they check it out and pay for it.
This was most likely why the conversion to common shares be epic bod.
You have to wonder how many people know about the news at this time.
I think it if I understand things correctly eltp will now be a take over target in the very near future.
I'll bet that they get scooped up pretty fast.
Or better yet they don't.
GLTA
I
Dr L
Can you please list all the negatives that come along with this patent approval.
I do think eltp is under the radar.
I would guess we will get lots of outside press in the coming weeks and months.
Pretty exciting.
GLTA
I sure am ready for news.
Patience is not my forte.
GLTA
Here is my answer.
Money Flow
Definition:
Money Flow is one of the more sophisticated and powerful technical indicators relating price to volume, and is calculated based in each tic during the trading day. The value increases by the shares traded on the level of an uptick, and decreased by the shares traded on the level of a downtick.
Therefore, if there is an uptick on 5,000 shares traded, money flow will increase by 5,000. If there is then a downtick on 600 shares traded, money flow will decrease by 600. If these two trades comprised the entire trading day, price would have ended even for the day, while money flow would have increased by 4,400.
Interpretation:
Signals are generated when there are divergences between the Money Flow and price.
When price is increasing while money is flowing out of the security, it is a warning of an impending collapse in the price of the stock.
When the price is trending downward while money is flowing into the security, it is a sign that some savvy buyers are accumulating the stocks.
How can money flow be positive and stock price decrease.
Is it calculated by the number/size of activity on bid vs ask?
GLTA
Conix
CMF represent money flow?
In the green, accumulation I assume.
Why do we always see the form 4s come in waves?
Buying or selling.
GLTA
Soldout a good portion of my position under .145.
Not the way you are supposed to do it but bought most of it back above .16 over the last two weeks.
Made finale purchase today.
Seems as thought iWeb has turned the corner. THe few cents I have missed won't make a whole lot of diff in the long run.
GLTA
What action will they take is what matters.
We are stuck until the powers that are involved let it run.
Which may be tomorrow or might be several months.
News used to move the stock now it appears it doesn't.
GLTA
and good time to buy more, there is a limit to how low this thing can be driven.
all imho
They are updating the counter very frequently.
For what its worth.
It is interesting,
GM did you buy down lower and sold out in the .085 range?
You are a sneaky little trader. lol
All this time I thought you had lost on ctyx when in reality, you have been trading with the best of em.
GLTA
Association of Mature American Citizens(AMAC) to Include Connectyx Technologies' MedFlash as Member Benefit
STUART, FL--(Marketwire - 07/14/11) - Connectyx Technologies Holdings Group, Inc.
(Pinksheets:CTYX) ("Connectyx"), www.connectyx.com, manufacturer and distributor of the MedFlash®, the nation's premier Personal Health and Wellness Management System (ePHM) for maintaining personal health records (PHR), announced today that the Association of Mature American Citizens (AMAC) is offering MedFlash as a member benefit. With its membership base now over 170,000 members, AMAC's member demographic mirrors the age range with the highest usage of PHR ages 50 and over.
Ronn Schuman, CEO of Connectyx, said, "We are very pleased to welcome members of AMAC to our MedFlash community. There is a natural 'fit' between the MedFlash personal health and wellness benefits and AMAC's rapidly growing membership base. As we continue to expand our distribution of MedFlash, we believe the adoption rate will increase as more consumers realize the benefits of accessing their medical records whenever necessary coupled with the health and wellness benefits. As with any new technology, it is necessary to capture the 'early adopters' before penetrating the broader market. With our new relationship with AMAC, we look forward to introducing MedFlash to such a target market". Sam Hassel, CEO of AMAC said, ""As we strive to provide our members with exceptional value, AMAC is looking forward to affording our members the latest technology in health management through their MedFlash health and wellness program."
MedFlash ® Features and Benefits
The MedFlash® PHM Portal features a 24/7/365 call center, a smart phone application and a USB flash drive. The MedFlash® PHM provides additional member benefits and services including instant access to a subscriber's Emergency Medical Profile and Personal Health Record in the event of an accident or a medical emergency. First Responders such as police, emergency medical technicians (EMT's) and firefighters have access to time critical information for victims who may be comatose or unable to communicate pertinent medical history information. The MedFlash® PHM can be accessed on any computer, whether in an ambulance or an emergency room, securely and with complete privacy via the Internet or by use of the USB drive. Lifestyle and wellness features are delivered to members that have the potential to result in significant health benefits to members following the healthcare advice. With the increasing focus on cutting
costs and risk mitigation by both employers and insurers, the MedFlash offers a low cost addition to the various initiatives necessary for maintaining and reducing costs of current healthcare
delivery systems. For more information, see www.medflash.com.
To be added to the corporate e-mail database for corporate press releases and industry updates,investors and shareholders are requested to send an e-mail to investorrelations@connectyx.com
About the Association of Mature American Citizens (AMAC) www.amac.us
AMAC is the leading alternative to the AARP offering membership benefits, discounts and political advocacy for Americans over 50. Discounts for AMAC members include hotel and motel discounts at over 7,000 locations across the country, discounts on auto and homeowners insurance, national discounts on rental cars, group health and life insurance, and preferred pricing on other products and services. AMAC continues to add substantial discounts at retail stores, restaurants and other businesses.
News
Connectyx Technologies Holdings Group, Inc. (PINKSHEETS: CTYX) ("Connectyx") www.connectyx.com, the manufacturer and distributor of the MedFlash, an innovative Personal Health and Wellness Management System (ePHM) designed for empowering the consumer to become more proactive in managing and maintaining their individual personal health records (PHR) and giving them access to affordable benefits and wellness programs, announced today that Connectyx Technologies has increased its affiliate network to over 70 marketing partners.
Connectyx has developed an affiliate program that provides the marketing partner with all the crucial tracking data of sales in real time reporting with a unique URL system at http://affiliate.medflash.com. In order to assist affiliates, Connectyx is utilizing social media to build the awareness of MedFlash health and wellness programs, and facilitating sales through its marketing partners by providing customizable affiliate links; www.medflash.com/sos. This cost efficient marketing plan is driving new memberships and maximizing the bottom line.
The company has added to the functionality of the MedFlash website to incorporate many of the changes in affiliate support. The Company anticipates that it will be releasing its new MedFlash consumer web portal over the next 30 days. This new look will modernize and increase the ease of use and navigation through the many MedFlash features and benefits for its members, affiliates and potential customers.
In the past two quarters, Connectyx has added to the list of benefits for MedFlash members, including, but not limited to:
MedFlash Members can now get discounts on prescriptions of up to 85% by utilizing the IRTRX, Inc program.
Telephonic 24/7 consultation by registered nurses through FONEMED, Inc. for MedFlash members requiring assistance in obtaining health information at no additional cost.
Connectyx has been approved by the Veterans administration to utilize the VA's enhanced Blue Button ® initiative for downloading personal medical records with MedFlash for VA and Medicare patients.
MedFlash has increased its social presence by launching its Facebook®, Twitter® and LinkedIn® pages, which it uses to attract new members and industry experts, resellers and its health care advisory board.
Connectyx has started developing its consumer pet network product, www.mypetsphr.com.
Ronn Schumann, CEO of Connectyx Technologies, said, "We are continuing to add new features and benefits that focus on engaging the consumer on the importance of becoming pro-active in managing the key elements of their health information. As we all know the rising cost of health care worldwide is mandating many changes and timing is critical for all of us as consumers of health products and services to start becoming more involved in keeping track of our own health profile, which includes managing our individual medical information in case of an emergency."
Schumann continued, "Management also believes that MedFlash, by providing its members access to wellness tools, they will begin shifting their individual lifestyle paradigm from traditional reactive care -- going to a doctor when they are sick -- and adopting more proactive health and wellness programs, i.e. proactive -- team medicine, which some of the leading health care systems are successfully incorporating; Mayo Clinic, University of Florida - Shands Hospital, Cleveland Clinic, amongst many others. Specifically, the aging population coupled with the rise in people suffering from chronic conditions that require management and monitoring has generated increased interest in MedFlash from our affiliates, who see the market opportunity, and the end users that realize that having access to their own medical records at all times is a true asset in their own personal healthcare."
In conclusion, Schumann noted, "We believe that by offering an affordable, easy to use health and wellness personal health manager that we will be successful in building a significant membership base and resulting revenues."
Association of Mature American Citizens (AMAC) and MASA Assist
Two examples of MedFlash affiliates are the Association of Mature American Citizens, commonly known as AMAC through their numerous radio ads and MASA Assist. AMAC has a membership base that exceeds 250,000 in the attractive demographic of people over the age of 55. Periodically, AMAC distributes a MedFlash specific e-mail to all its members which has always resulted in additional sales.
MASA Assist is a thirty-five year old established international organization that is dedicated to providing its 500,000+ members with lifesaving, emergency assistance while they are at home, on the job, or traveling the world. MASA Assist protects its members 24 hours a day, 365 days a year from catastrophic financial loss when medical emergencies arise requiring air and/or ground ambulances. The immediate accessibility of personal medical records is a decided plus for all travelers.
These particular strategic partners, along with the fifty other affiliates, ensure peace of mind for MedFlash members and their families by always having their medical records available to themselves and emergency personnel, all at a very affordable cost. These two representative affiliates and others are a source of ongoing new signups for MedFlash providing both the affiliates benefit programs and Connectyx with revenue.
Connectyx Developing Veterinary Records for Pets (MyPetsPHR)
To tap into the huge market of doting pet owners, Connectyx has initiated development of its Personal Health Records (PHR) for pets -- MyPetsPHR will utilize the Internet Web domain www.mypetsphr.com. Similar to MedFlash, the MyPetsPHR will offer a secure web portal suite for a pet's medical information (shots, vaccines) in addition to a USB flash drive and smart phone applications with QR Scan code capability. The MyPetsPHR will include the pet owner's contact information to expedite a pet's recovery when lost. MyPetsPHR will also include pet benefits, pet insurance, access to pet-friendly hotels, dog parks and more.
If we have to wait for that, fine.
Like you, I would love to this run on other news.
I believe profitablity will happen this quarter.
GLTA
This volume is really small compared to what I have seen on this stock when it runs.
The days are comming when we will trade 10 mil in the first hour.
I do like the increase though. Would love to see 6-8 mill today, even if the price does not move up much.
Vol preceeds price.
Email from IR
From Yahoo Board.
Nothing new.
Diane does seemed to feel eltp is pretty pumped about the deal.
ME: Good morning, Is there a reason why the private company's name in yesterdays PR can't be disclosed? Thanks.
IR: Dear -------,
In the pharmaceutical industry, it is preferred to release as little information as possible for competitive reasons. You really don’t want others to know what you are working on.
The company we have entered into the development agreement with is a private company, and therefore does not have to disclose anything.
On the other hand, the agreement is with Elite who is public, which is required to disclose information to the stockholders without compromising strategic/competitive information.
There is a fine line that we sometimes have to walk to be in compliance with disclosure rules but still maintain the strategic/competitive edge in the industry. Until a product is approved by the FDA it is best that the competition does not know what you are working on.
If the partner had their way, they would have preferred that nothing be released.
Elite is very pleased to be involved with the development of this product. The product is not named for competitive reasons described above. We have historically not disclosed milestone payments on any of our contacts, but I can assure you that the amounts are in line with industry standards.
This product will be an additional revenue stream from start to finish. We will be paid for the development work, paid for the manufacturing and packaging upon approval, as well paid to conduct and maintain laboratory work for the product.
We are thrilled to have yet another product under development in addition to our own products.
This is a great opportunity for Elite and I am very pleased this company has chosen Elite to help them with this product for the United States market and its territories.
Best regards,
Dianne
ME: Hey thanks a lot! Great news! Is it ok to post your response on the ELTP message board so other shareholders can be aware of this. Some people were worried about this PR because of the company being in China and not releasing the name. I think this will clear up any confusion. Again, thanks a lot!
IR: -------,
The pharmaceutical industry likes to keep things close to the vest.
Private companies don’t have to disclose anything and is difficult for them when they do business with a public company.
Even with Elite being a public company, we also don’t disclose certain things also because of competitive reasons.
For instance, if you look back at other contracts, the same information was redacted, with the exception of Hi-Tech. I think the category was disclosed but nothing more.
This product is a branded (NEW DRUG), not a generic product which will be marketed in the United States and its territories.
We are excited to be involved with this product.
Best regards,
Dianne
Volume -Looks like eltp might run.
Although not earth shattering news, the company continues to add to their bottom line.
I can't foresee this going lower with all the positives.
GLTA
Good buy
I will do the same.
Once we break a penny, she is off to the races.
We are due for some news.
The news might be pretty big as the buying has come in pretty strong the past few days,.
My guess is there was a leak and the folks who know whats going on are buying like crazy down here.
Seems like it happens a lot with small companies one little bit of info gets out and the volume spikes.
Anyway, I think we reach a penny easily and would not be surprised that are new base might be in that area too.
GLTA enjoy the ride and higher highs.
Great to see the price moving up.
I think we will break 200 dma pretty easy.
But we must remember with our profits and excitement there are those among us who are very pained to see the price go up.
GLTA
You are correct.
Ctyx looks ready to run here.
Anything under a penny is almost a certain double.
It has a low float and is due for news.
GLTA